Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity

被引:61
作者
Miyagawa, E
Yoshida, T
Takahashi, H
Yamaguchi, K
Nagano, T
Kiriyama, Y
Okochi, K
Sato, H
机构
[1] Fujirebio Inc, Ube Res Labs, Ube, Yamaguchi 7900135, Japan
[2] Onoda City Hosp, Dept Pediat, Yamaguchi 7560088, Japan
[3] Yamaguchi Univ, Sch Med, Inst Lab Anim, Ube, Yamaguchi 7550067, Japan
[4] Fukuoka Red Cross Blood Ctr, Fukuoka 8188858, Japan
关键词
human parvovirus B19; TCID50; KU812Ep6;
D O I
10.1016/S0166-0934(99)00105-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A human parvovirus B19 (B19) infectivity assay was developed using the erythroid cell line, KU812Ep6. KU812Ep6 was cloned for high efficiency infection with B19 in vitro, in the presence of erythropoietin by a limiting dilution method from the parent cell line, KU812. B19 was effectively propagated in KU812Ep6 and was detected for B19 antigens, VP1 and VP2. The titers of B19 positive sera measured with KU812Ep6 cells were in the range of 10(6) to 10(8) TCID50 ml. This KU812Ep6 infectivity assay had a 10(3)-10(4.5) higher sensitivity than the colony forming unit-erythroid (CFU-e) injury assay. It was calculated that one TCID50 needed 10(3) B19 genome copies, judging from the infectivity assay and semi-quantitative PCR. The KU812Ep6 infectivity assay was also used to determine infectivity of B19 in vitro, and to evaluate inactivation, as well as clearance of the virus. The inactivation of B19 by heating was carried out and infectivity declined from 10(4) TCID50 ml to < 10 TCID50 ml (lower limit of detection) at 60 degrees C for 3 h or at 70 degrees C for 30 min, but only decreased to 10(2.5) TCID50 ml at 50 degrees C for 8 h. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:45 / 54
页数:10
相关论文
共 36 条
[11]   B19 PARVOVIRUS DNA IN SOLVENT DETERGENT-TREATED ANTI-HEMOPHILIA CONCENTRATES [J].
LEFRERE, JJ ;
MARIOTTI, M ;
THAUVIN, M .
LANCET, 1994, 343 (8891) :211-212
[12]  
MORTIMER PP, 1983, LANCET, V2, P482
[13]   A HUMAN PARVOVIRUS-LIKE VIRUS INHIBITS HEMATOPOIETIC COLONY FORMATION INVITRO [J].
MORTIMER, PP ;
HUMPHRIES, RK ;
MOORE, JG ;
PURCELL, RH ;
YOUNG, NS .
NATURE, 1983, 302 (5907) :426-429
[14]   SUCCESSFUL REPLICATION OF PARVOVIRUS-B19 IN THE HUMAN MEGAKARYOCYTIC LEUKEMIA-CELL LINE MB-02 [J].
MUNSHI, NC ;
ZHOU, SZ ;
WOODY, MJ ;
MORGAN, DA ;
SRIVASTAVA, A .
JOURNAL OF VIROLOGY, 1993, 67 (01) :562-566
[15]  
NAKAZAWA M, 1989, BLOOD, V73, P2003
[16]   REPLICATION OF THE B19 PARVOVIRUS IN HUMAN-BONE MARROW CELL-CULTURES [J].
OZAWA, K ;
KURTZMAN, G ;
YOUNG, N .
SCIENCE, 1986, 233 (4766) :883-886
[17]   NOVEL TRANSCRIPTION MAP FOR THE B19 (HUMAN) PATHOGENIC PARVOVIRUS [J].
OZAWA, K ;
AYUB, J ;
HAO, YS ;
KURTZMAN, G ;
SHIMADA, T ;
YOUNG, N .
JOURNAL OF VIROLOGY, 1987, 61 (08) :2395-2406
[18]  
OZAWA K, 1988, J BIOL CHEM, V263, P10922
[19]  
PATTISON JR, 1981, LANCET, V1, P664
[20]   Human parvovirus B19 and blood products [J].
Prowse, C ;
Ludlam, CA ;
Yap, PL .
VOX SANGUINIS, 1997, 72 (01) :1-10